Anaxomics is a global leader in Drug Discovery, Predictive Safety and Drug Reprofiling by using the newest Systems Biology technologies.
Anaxomics implements Systems Biology through its proprietary technology Therapeutic Performance Mapping System (TPMS), a top-down approach which molecularly models human pathophysiology in silico through the use of artificial intelligence.
We offer our clients solutions to enhance the value of their drug pipeline: Solutions in Safety, Pipeline Valuation, and Drug Reprofiling.
Biomarkers are defined as objectively measurable parameters that reflect pathogenic processes or pharmacologic responses to therapeutic intervention. More specifically, molecular biomarkers are those that can be detected using generally accepted techniques from molecular biology, such as genomics or proteomics. Molecular biomarkers are measured directly or indirectly through metabolites in urine, blood, saliva and other body fluids.
The evaluation of biomarkers as indicators of a particular disease or some other physiological state is often crucial for the successful progression of an investigation. New developments in the so-called 'omics' sciences are increasing the amount of data available for analysis from the molecular perspective. However, finding a biomarker that properly correlates with the physiological state under study and that it is also highly specific to this state is difficult. Although a number of signals can be detected as increased / decreased expression levels in a pool of proteins, if we are not able to put those signals in biological context, their usefulness can be severely impaired.
Anaxomics employs its Therapeutic Performance Mapping System (TPMS) proprietary technology to accurately identify biomarkers through the mathematical modelling of pathological conditions and other physiological situations. In this manner, TPMS can identify reliable biomarkers whose differential activity or expression is associated with a particular physiological state. Our method has been proved to achieve with high degrees of confidence, as demonstrated in laboratory studies performed by our partners.
Biotechnological and pharmaceutical companies need to maximize the value of their pipeline, and one of the most cost-effective strategies is to identify new indications for drugs already in the market or in the later stages of clinical development. Even if they are not effective enough for the intended initial indication, these compounds have proven to be safe and, consequently, have to undergo much less regulatory scrutiny.
Drug repositioning can no longer rely on serendipity, but has to be a directed, rational and optimized process. Sticking close to this philosophy, Anaxomics’ TPMS proprietary technology explores the full potential of systems biology analysis in order to identify new indications for already existing drugs. By navigating through the pathophysiological maps of diseases, we can discover valuable targets and identify compounds that modulate them (TPMS).
Despite the recent advancements in drug discovery, the attrition rates due to lack of efficacy and safety issues remain high. In vitro and in vivo assays, typically used to evaluate efficacy and safety, are time-consuming, expensive and partially representative of responses in humans.
To address the urgent need for better methods, Anaxomics offers an innovative solution based on systems biology, the TPMS© technology, for evaluating and predicting safety and efficacy aspects of drugs. We put this service at the disposal of pharmaceutical companies and research centres working in drug development, including preclinical and clinical stages.
TPMS determines the safety and efficacy profile of compounds on the basis of their known and predicted targets, analysing the consequences of their modulation in human physiology. As described in the figure on the right, TPMS considers the interaction of multiple targets and off-targets at the same time, as well as their contribution to any disease or indication.
High throughput techniques (such as microarrays or mass spectrometry), with their ability to generate enormous amounts of data, introduce new challenges for analysis and interpretation. Classical statistical treatments are useful to identify relevant changes in gene expression or protein activity, but fail at providing a global picture of the biological phenomena under study. For this reason, Anaxomics offers a complementary approach based on systems biology that is able to extract biologically and clinically relevant information from your results.
Therapeutic Performance Mapping System (TPMS) generates mathematical models that faithfully simulate human physiology by adjusting to the available biological knowledge. Data from high throughput experiments is integrated into these virtual systems, so that it can be evaluated while taking into account the global, complex relationships that occur inside living beings. The models encompass various organization levels, ranging from individual cell types to entire human populations, so each analysis is performed in its due context.
When high throughput data about different groups of subjects (cohorts) is submitted, TPMS generates specific mathematical that simulate the unique properties of each cohort. Then, it identifies mechanistic explanations that help you understand the differences between populations and highlight any related clinical issue, such as pathological manifestations or adverse events in case of drug treatment.
This innovative interpretation contextualizes your results in the frame of well-established scientific knowledge, instead of analyzing it as a single, isolated experiment. In this manner, your own research is complemented and refined using results from past studies.
With the emergence of a molecular target-based paradigm in the pharmaceutical industry, acquiring knowledge of a compound's target profile has become an essential first step in drug discovery. A deep comprehension of drugs' molecular site of action allows you to maximize the value of your discoveries by evaluating potential new indications, anticipating adverse events and avoiding pitfalls in clinical trials.
On this account, Anaxomics has developed an integrative approach for new target discovery that combines the latest advances in systems biology with structure-based techniques. Our mixed strategy allows pharmaceutical and biotechnological companies to fully understand the target profile of the compounds under development or already in the market.
In short, we employ various chemical modelling approaches to identify potential targets and off-targets of a compound. Later, we filter and rank the results from these techniques with our proprietary Therapeutic Performance Mapping System (TPMS), so that only those that may explain clinical and preclinical observations remain.
Anaxomics has developed an integrative strategy for new target discovery that combines the latest advances in systems biology with structure-based techniques. Our combined approach allows pharmaceutical and biotechnological companies to fully understand the target profile of the compounds under development or already in the market.
Anaxomics TPMS© technology employs the latest breakthroughs in systems biology to generate mechanistic hypotheses that explain how a given stimulus drives a biological effect. These hypotheses, termed mechanism of action (MoA), link certain genes, proteins or drugs with known physiological or pathophysiological pathways based on the holistic analysis of complex biological networks.
Thanks to the biological and clinical information embedded in TPMS, our MoAs are consistent with reality, hence providing a framework for testing and validating the consequences of a stimulus on a molecular level. MoAs are visualized in the form of graphical representations where nodes are genes or proteins and lines show the relationship between them.
Anaxomics biotech, SL has not received any reviews.
Anaxomics biotech, SL has not received any endorsements.